



AMENDMENTS TO THE CLAIMS


1. (CURRENTLY AMENDED) A compound of formula (Ia) or (Ib):




or a pharmaceutically acceptable salt, ~~prodrug~~, hydrate, tautomer or solvate thereof, wherein:

X is O or S;

R¹ is selected from the group consisting of





where  $R^{2a}$  is independently selected from the group consisting of:  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl,  $(C_3-C_{10})$ cycloalkyl,  $(C_5-C_{10})$ aryl,  $(C_1-C_6)$ alkylaryl, amino, carbonyl, carboxyl,  $(C_2-C_6)$ acid,  $(C_1-C_6)$ ester,  $(C_5-C_{10})$ heteroaryl,  $(C_5-C_{10})$ heterocyclyl,  $(C_1-C_6)$ alkoxy, nitro, halo, hydroxyl,  $(C_1-C_6)$ alkoxy $(C_1-C_6)$ ester, and where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, amino, acid, ester, heteroaryl, heterocyclyl, and alkoxy of  $R^{2a}$  is optionally substituted by at least one moiety independently selected from the group consisting of halo,  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, perhalo $(C_1-C_6)$ alkyl, phenyl,  $(C_3-C_{10})$ cycloalkyl,  $(C_5-C_{10})$ heteroaryl,  $(C_5-C_{10})$ heterocyclic, formyl, NC-,  $(C_1-C_6)$ alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-,  $(C_1-C_6)$ alkyl-O-(C=O)-,  $(C_1-C_6)$ alkyl-NH-(C=O)-,

((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N)-(C=O)-, O<sub>2</sub>N-, amino, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, H<sub>2</sub>N-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-NH-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-HN-(C=O)-NH-, (phenyl)<sub>2</sub>N-(C=O)-NH-, phenyl-HN-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (phenyl)<sub>2</sub>N-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>NH-, phenyl-SO<sub>2</sub>NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, phenyl-SO<sub>2</sub>-, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-, (C<sub>1</sub>-C<sub>6</sub>)ester-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-, phenyl-(C=O)-O-, H<sub>2</sub>N-(C=O)-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-O-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl)<sub>2</sub>N-(C=O)-O-;  
~~a saturated, unsaturated, or aromatic C<sub>3</sub>-C<sub>20</sub> mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein R<sup>1</sup> can optionally be further independently substituted with at least one moiety independently selected from the group consisting of:~~ carbonyl, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, hydroxy, oxo, mercapto, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>5</sub>-C<sub>10</sub>)aryl or (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)aryloxy or (C<sub>5</sub>-C<sub>10</sub>)heteroaryloxy, (C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl- and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, cyano, nitro, carbamoyl, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, (C<sub>5</sub>-C<sub>10</sub>)arylcabonyl, (C<sub>5</sub>-C<sub>10</sub>)aryloxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, and (C<sub>5</sub>-C<sub>10</sub>)arylsulfonyl;

each R<sup>3</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkyl HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoO<sub>2</sub>S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-,

(C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-[(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, H<sub>2</sub>N(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-,

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R<sup>3</sup> is optionally substituted by at least one substituent independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, H<sub>2</sub>N-, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, and (C<sub>1</sub>-C<sub>6</sub>)alkylHN-;

s is an integer from one to five;

R<sup>4</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylHN-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoO<sub>2</sub>S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, H<sub>2</sub>N(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-,


where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R<sup>4</sup> is optionally substituted by at least one substituent independently selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, H<sub>2</sub>N-, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylHN-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl and (C<sub>5</sub>-C<sub>10</sub>)heterocyclic; with the proviso that when R<sup>4</sup> is a substituted phenyl moiety, then (a) R<sup>1</sup> is not naphthyl, phenyl or anthracenyl and (b) if R<sup>1</sup> is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms

independently selected from N, O and S, then the fused cyclic ring of said  $R^1$  moiety is substituted;


with the proviso that when  $R^4$  is  $NH_2$  and X is S, then  $R^1$  is not an amino-substituted pyridyl or pyrimidinyl moiety; and

with the proviso that when in formula (Ia)  $R^4$  is  $CH_3$  and X is S,  $R^1$  is not a 3, 4-dimethoxy substituted phenyl moiety.


2. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is




3. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is




4. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is




5. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is




6. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is



7. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is



8. (ORIGINAL) A compound of claim 1, wherein  $R^1$  is



9. (ORIGINAL) A compound of claim 1, wherein X is O; s is one to two; R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and R<sup>4</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or amino.
10. (ORIGINAL) A compound of claim 1, wherein X is S; s is one to two; R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and R<sup>4</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or amino.
11. (CURRENTLY AMENDED) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
12. (CURRENTLY AMENDED) A method of treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the animal or human suffering from the TGF-related disease state selected from the group consisting of ~~cancer~~, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.
13. (CANCELED)
14. (NEW) A compound selected from the groups consisting of ;
  - 2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-methyl-pyridine;
  - 2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-pyridine;
  - 2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-methoxy-pyridine;
  - 2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-trifluoromethyl-pyridine;
  - 2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-2H-benzotriazole;
  - 4-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;

1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-1H-benzotriazole;  
6-(4-Pyridin-2-yl-oxazol-5-yl)-quinoxaline;  
6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoxaline;  
6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;  
6-(4-pyridin-2-yl-oxazol-5-yl)-quinoline;  
2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-ethyl-pyridine;  
2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-propyl-pyridine;  
6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-benzothiazole;  
2-(4-Benzo[1,3]dioxol-5-yl-oxazol-5-yl)-6-methyl-pyridine;  
4-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;  
1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-1H-benzotriazole;  
2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-2H-benzotriazole;  
6-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;  
6-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoxaline;  
2-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;  
{4-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-pyridin-2-yl}-phenyl-amine;  
2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-oxazol-5-yl)-6-methyl-pyridine;  
1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-1H-benzotriazole;  
2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-2H-benzotriazole;  
6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;  
6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoxaline;  
2-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;  
{4-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-pyridin-2-yl}-phenyl-amine;  
4-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;  
4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
4-(3-Methyl-3H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
5-(6-Methyl-pyridin-2-yl)-4-quinolin-6-yl-thiazol-2-ylamine;  
5-(6-Methyl-pyridin-2-yl)-4-quinoxalin-6-yl-thiazol-2-ylamine;  
5-(6-Methyl-pyridin-2-yl)-4-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;  
{4-[2-Amino-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;  
5-(6-Methyl-pyridin-2-yl)-4-quinolin-4-yl-thiazol-2-ylamine;



4-(6-Methyl-pyridin-2-yl)-5-quinolin-6-yl-thiazol-2-ylamine;  
5-(3-Methyl-3H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
5-(2-Methyl-2H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
5-Benzo[1,3]dioxol-5-yl-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;  
4-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-thiazol-2-ylamine;  
4-(6-Methyl-pyridin-2-yl)-5-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;  
{4-[2-Amino-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;  
4-(6-Methyl-pyridin-2-yl)-5-quinolin-4-yl-thiazol-2-ylamine;  
6-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;  
1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-1H-benzotriazole;  
2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-2H-benzotriazole;  
2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-oxazol-4-yl)-6-methyl-pyridine;  
6-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoxaline;  
2-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-[1,5]naphthyridine;  
{4-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-pyridin-2-yl}-phenyl-amine;  
4-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;  
1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;  
2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;  
2-(5-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-6-methyl-pyridine;  
6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;  
2-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;  
{4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;  
4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;  
6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;  
1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;  
2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;  
2-(4-Benzo[1,3]dioxol-5-yl-thiazol-5-yl)-6-methyl-pyridine;  
6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;  
2-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;  
{4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;  
4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;  
6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;  
1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;

2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;  
2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-4-yl)-6-methyl- pyridine;  
6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;  
2-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;  
{4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;  
4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;  
6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;  
1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;  
2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;  
2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-5-yl)-6-methyl-pyridine;  
6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;  
2-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;  
{4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;  
4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline and  
6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline; or a pharmaceutically  
acceptable salt thereof.

15. (NEW) A pharmaceutical composition comprising a therapeutically effective amount  
of a compound of claim 14 and a pharmaceutically acceptable carrier.